Novo Nordisk Says Wegovy Helps Young Children Lose Weight
A new trial shows the weight-loss drug Wegovy helps lower body mass index in children under 12.

Childhood obesity creates health risks that can last a lifetime. Today, doctors have few tools to treat young kids who struggle with severe weight issues. Novo Nordisk aims to change that reality with its hit drug Wegovy.
The drugmaker ran a clinical trial with children under the age of 12. Novo Nordisk says Wegovy helped these kids lower their body mass index and cut obesity rates. The company already sells Wegovy for teens ages 12 and older. Now it wants to expand the drug to younger patients who currently have no approved medical options.
Success in younger age groups could open a fresh market for Novo Nordisk. Demand for weight-loss shots continues to grow around the world. Regulators must still review the trial data before doctors can write these prescriptions.
For families, this progress points to new medical answers for early health problems. For investors, it shows that drugmakers see room to expand their top-selling treatments.
Source: CNBC




